Designing mRNAs
with generative
AI excellence

Raina is revolutionizing mRNA design with GEMORNA, our cutting-edge generative AI platform that is unlocking the full potential of mRNA-based therapeutics.

Learn more
RNA
AI
RAINA
Where RNA meets AI
Technology

Advancing mRNA therapeutics with AI-driven design

Raina provides solutions to the key challenges in next-generation mRNA therapeutics using a generative AI platform.

1

Cutting-edge Generative AI Engine

2

Deep Expertise in mRNA Biology and Therapeutic Design

3

High-throughput Gene Synthesis and Experimental Validation

Cutting-edge Generative AI Engine

Leveraging its generative AI engine, Raina explores an expansive multi-dimensional design space and generates candidates with enhanced translational capacity, durability, and potency.

Multi-dimensional sequence optimization incorporating latent space representations of mRNA features
Enhanced expression and stability across targets and applications — experimentally validated
Zero-shot designs with high success rates — accelerating pre-clinical timelines

Deep Expertise in mRNA Biology and Therapeutic Design

The Raina team brings decades of expertise in RNA biology and drug development to advance mRNA design, leveraging this insight to steer the creation of AI tools for precise mRNA optimization.

RNA biology expertise from leading researchers
Drug development experience across therapeutic areas
Proven experience in AI-driven mRNA optimization

High-throughput Gene Synthesis and Experimental Validation

Raina's lab capabilities enable rapid synthesis and parallel screening of AI-designed sequences. This closed-loop experimental platform accelerates the discovery of potent mRNA therapeutics with unmatched speed and accuracy.

High-throughput gene synthesis platform
Large-scale screening capability
Closed-loop design-test cycles
01010011
11000101
00110110
Team

Vision, Leadership & Expertise

Leading experts in RNA biology, AI, and drug development working together to transform mRNA therapeutics.

Timothy Lu

Timothy Lu in

M.D., Ph.D.

Co-Founder, Chairman

Jicong Cao

Jicong Cao in

Ph.D.

Co-Founder, CEO

He Zhang

He Zhang in

Ph.D.

Co-Founder, CTO

Joel Edwards

Joel Edwards in

M.S., MBA

Chief Corporate Development Officer

Jeff Coller

Jeff Coller in

Ph.D.

Scientific Advisor, Bloomberg Distinguished Professor, JHU

Latest News

Company Updates & News

Stay updated with our latest breakthroughs in mRNA therapeutics.

Follow us

Experimental data underscores the untapped potential of mRNA sequence optimization by GEMORNA platform in advancing in vivo CAR-T therapies

Raina creates mRNA vaccines that consistently surpass existing commercial or patented benchmarks

The team at Raina is looking forward to our partnering meetings at Bio International in Boston

Experimentally validated Generative AI platform for CDS optimization

Raina Biosciences will be attending the Bio Europe conference in November
Scientific Research Laboratory

Recent News

Raina Biosciences Unveils Breakthrough Generative AI Platform for mRNA Therapeutics Featured in Science

AI-based program designs new mRNA

Raina Biosciences Unveils Advanced Generative AI Platform for mRNA Therapeutics

Raina Biosciences Unveils GEMORNA, a Revolutionary AI Platform for mRNA Design
Publications

Scientific Publications

Our research contributions to advancing the field of mRNA therapeutics and RNA biology.

bioRxiv

Deep generative models design mRNA sequences with enhanced translational capacity and stability

Science • Aug 28, 2025

Nature

Algorithm for optimized mRNA design improves stability and immunogenicity

Nature • May 02, 2023

Nature Communications

High-throughput 5′ UTR engineering for enhanced protein production in non-viral gene therapies

Nature Communications • July 06, 2021

Cell

Synthetic RNA-based immunomodulatory gene circuits for cancer immunotherapy

Cell • November 16, 2017

Cell

Multiplexed and programmable regulation of gene networks with an integrated RNA and CRISPR/cas toolkit in human cells

Molecular Cell • May 22, 2014

Nature Communications

LinearCoFold and LinearCoPartition: linear-time algorithms for secondary structure prediction of interacting RNA molecules

Nucleic Acids Research • August 31, 2023

PNAS

Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM

PNAS • February 10, 2016

PNAS

A universal strategy for regulating mRNA translation in prokaryotic and eukaryotic cells

Nucleic Acids Research • April 06, 2015

Nature Biotechnology

Massively parallel high-order combinatorial genetics in human cells

Nature Biotechnology • September 01, 2015

Nature Biotechnology

Bidirectional regulation of mRNA translation in mammalian cells by using PUF domains

Angewandte Chemie International Edition • 26 March, 2014

Nature Communications

Light-inducible activation of target mRNA translation in mammalian cells

Chemical Communications • Aug 08, 2013

Partnerships

Your partner in mRNA innovation

Raina is the trusted partner to accelerate your mRNA therapeutic development programs.

Contact Us

Ready to Transform mRNA Therapeutics?

Connect with our team to explore how GEMORNA can accelerate your next breakthrough.

Let's unlock the full
potential of mRNA
therapeutics
together.

Reach out with any questions or ideas.

AI-Powered